HemogloBind™ Used for Hemoglobin Depletion in Site-Specific GlcNAcylation of Human Erythrocyte Proteins: Potential Biomarker(s) for Diabetes Mellitus study

HemogloBind™ Used for Hemoglobin Depletion in Site-Specific GlcNAcylation of Human Erythrocyte Proteins: Potential Biomarker(s) for Diabetes Mellitus study

MONMOUTH JUNCTION, N.J.HemogloBind™ is engineered for a high degree of hemoglobin binding selectivity and does not cross react with most common serum components. HemogloBind™’s binding capacity for hemoglobin is approximately 10mg/ml of hemoglobin. HemogloBind™ is used mostly on hemolysed serum. 

Details about HemogloBind™
http://www.biotechsupportgroup.com/HemogloBind-Hemoglobin-Depletion-From-Hemolyzed-p/h0145.htm
HemogloBind™ Product Sheet and Protocol.
http://www.biotechsupportgroup.com/v/vspfiles/templates/257/pdf/HemogloBind%20Product%20Sheet%20073015MK.pdf

Research studies that mention HemogloBind™:

Kyoungsook Park, Christopher D. Saudek, and Gerald W. Hart (2010) Increased Expression of β-N-Acetylglucosamindase (O-GlcNAcase) in Erythrocytes from Prediabetic and Diabetic Individuals. Diabetes. 59(7):1845-50.
Zihao Wang, Kyoungsook Park, Frank Comer1, Linda C. Hsieh-Wilson, Christopher D. Saudek, and Gerald W. Hart (2008) Site-Specific GlcNAcylation of Human Erythrocyte Proteins: Potential Biomarker(s) for Diabetes Mellitus. Diabetes 58, 309-317.
Site-Specific GlcNAcylation of Human Erythrocyte Proteins: Potential Biomarker(s) for Diabetes Mellitus.

O-GlcNAc actively cycles on erythrocyte, regulates insulin signaling and is a mediator of glucose toxicity. Therefore studying it may reveal potential biomarker for diagnoses of diabetes. Highly efficient enrichment methods based Hemoglobind overcome the challenges of low stoichiometry, suppressed ionization efficiency in presence of unmodified peptides, and intrinsic lability in gas phase mass spectrometric methods. In this paper, authors used Hemoglobind to study erythrocyte proteins and compared it with their abundance between normal and diabetic samples proteins. Blood samples were obtained from normal and diabetic patients collected into a vial containing EDTA and OGlcNAcase inhibitor PUGNAc. Next the researchers fractionated the blood cells to isolate erythrocytes. After erythrocytes were lysed and centrifuged, the supernatant containing hemoglobin was partially depleted by HemogloBind™ from Biotech Support Group

About Biotech Support Group LLC

Biotech Support Group LLC is a leading developer of proteomic and genomic sample preparation and enrichment products. Its principal products include: AlbuVoid™ for albumin depletion, Cleanascite™ for lipid adsorption and clarification, HemogloBind™ & HemoVoid™ for hemoglobin removal, NuGel™ for functional & chemical proteomics, and ProCipitate™ & ProPrep™ for nucleic acid isolation. For more information, go to www.biotechsupportgroup.com.

CONTACTS:

Dr. Swapan Roy & Matthew Kuruc
Biotech Support Group LLC
1 Deer Park Drive, Suite M
Monmouth Junction NJ 08852
732-274-2866 Worldwide
800-935-0628 North America
sales@biotechsupportgroup.com
http://www.biotechsupportgroup.com